Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TKI258 intermittent dosing in advanced or metastatic renal cell carcinoma
NL-OMON35681Phase 2Active, not recruiting
- Sponsor
- Novartis
- Start
- Jun 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of dovitinib in renal cell carcinoma (RCC) (2 cohorts), sponsored by Novartis. Primary endpoint: Clinical benefit at 8 weeks. Started Jun 2009; status: active, not recruiting.
02
Drugs
dovitinib
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NL-OMON35681.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON35681.